Yang Bo Ram, Oh In-Sun, Li Junqing, Jeon Ha-Lim, Shin Ju-Young
Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea.
School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea.
J Psychosom Res. 2020 Aug;135:110153. doi: 10.1016/j.jpsychores.2020.110153. Epub 2020 May 23.
We aimed to investigate whether concomitant use of benzodiazepines and opioids is associated with an increased risk of death in a population-based case-crossover setting.
We conducted a case-crossover study using the National Sample Cohort database. We introduced a 30-day hazard period before the onset of death and three consecutive previous 30-day control periods with a 30-day washout period. The use of opioids and/or benzodiazepines during the hazard period was compared with that in the three control periods. We performed the conditional logistic regression analysis to estimate the adjusted odds ratios (aORs) and their 95% confidence intervals (CIs).
A total of 13,161 individuals who previously used benzodiazepines or opioids and died were included in the study. The risk of death was higher in patients with concomitant use of benzodiazepines and opioids (aOR, 1.86; 95% CI, 1.71-2.02) than in those who used either benzodiazepines or opioids only. In the subgroup analysis among concomitant users, the mortality risks were highest in patients aged less than 20 years (aOR, 3.85; 95% CI, 1.65-8.99), male patients (aOR, 2.20; 95% CI, 1.93-2.51), and patients with renal disease (aOR, 2.42; 95% CI, 1.57-3.74).
In this study, concomitant use of benzodiazepines and opioids was associated with a higher risk of death compared with use of a single drug. The risks and benefits of co-prescribing of benzodiazepines and opioids must be weighed carefully.
我们旨在研究在基于人群的病例交叉研究中,同时使用苯二氮䓬类药物和阿片类药物是否会增加死亡风险。
我们使用国家样本队列数据库进行了一项病例交叉研究。我们在死亡发生前引入了一个30天的危险期,并设置了三个连续的前30天对照期,中间有一个30天的洗脱期。将危险期内阿片类药物和/或苯二氮䓬类药物的使用情况与三个对照期内的使用情况进行比较。我们进行了条件逻辑回归分析,以估计调整后的优势比(aORs)及其95%置信区间(CIs)。
共有13161名曾使用过苯二氮䓬类药物或阿片类药物并死亡的个体纳入研究。同时使用苯二氮䓬类药物和阿片类药物的患者的死亡风险(aOR,1.86;95%CI,1.71 - 2.02)高于仅使用苯二氮䓬类药物或阿片类药物的患者。在同时使用者的亚组分析中,死亡风险在年龄小于20岁的患者(aOR,3.85;95%CI,1.65 - 8.99)、男性患者(aOR,2.20;95%CI,1.93 - 2.51)和患有肾脏疾病的患者(aOR,2.42;95%CI,1.57 - 3.74)中最高。
在本研究中,与单一药物使用相比,同时使用苯二氮䓬类药物和阿片类药物与更高的死亡风险相关。必须仔细权衡苯二氮䓬类药物和阿片类药物联合处方的风险和益处。